A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking historyMichael Smylie, Helen J. Ross, Afshin Dowlati et al.|Journal of Clinical Oncology|2007Cited by 32